SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

M Hergersberg1 , C Murtin2 , H Laeng3 , M Moschopoulos3 , L Mariani4 , A Huber1 , J Weis2 , U Roelcke5

1Zentrum für Labormedizin, Kantonsspital Aarau, 5001 Aarau, 2Institut für Pathologie, Universität Bern, 3Pathologisches Institut, Kantonsspital Aarau, 4Neurochirurgische Klinik, Inselspital, Universität Bern, 5Neurologische Klinik, Kantonsspital Aarau

Background: In contrast to other astrocytomas and glioblastomas, oligodendrogliomas and oligoastrocytomas have often been found to be chemosensitive when they carry allelic deletions on chromosome arms 1p and 19q. Furthermore there is a correlation between genetic changes and chemotherapeutic response as well as prognosis. Recently, it has been argued that the mutational changes and the location of oligoastrogliomas are correlated. The loss of genetic material in tumour tissues is identified through the comparison of DNA sequences from tumour tissue and non-transformed tissue. We summarize the results of the diagnostic loss of heterozygosity (LOH) analyses at different microsatellite polymorphisms on chromosome arms 1p and 19q.
Material and methods: Samples from 103 patients were analyzed (37 in Aarau and 66 in Bern). The samples are diagnostically differentiated in oligodendroglioma and oligoastrocytoma of stages II and III (WHO), as well as 30 astrocytoma and glioblastoma. The microsatellite polymorphisms used in Aarau were D1S508, D1S2734, D1S199, D19S219, D19S112, D19S596, and D19S412 and those used in Berne were D1S468, D1S1612, D1S228, D1S214, D19S219, D19-HRC and D19S412. All those primers were from the genome database (GDB). Size and amount of the PCR products was determined either by electrophoresis on sequencing gels, or using an ABI310 automatic capillary sequencer.
Results and Discussion: In 18 out of 23 oligodendrogliomas and 19 out of 35 oligoastrocytomas, LOH of both 1p and 19q was identified. In Berne, altogether 30 samples from astrocytomas and glioblastomas with different WHO staging have also been tested for LOH. Interestingly, in rare cases LOH on 1p and 19q is also found in these tumours. This has also been reported in literature, and indicates a higher degree of molecular heterogeneity in these two groups of tumours.


07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr


pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen


17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers